# Surgical Revascularization Outcomes After Oral Anticoagulation or Antiplatelets

Study · id `cardio:ct-nct03605433` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03605433](<https://clinicaltrials.gov/study/NCT03605433>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03605433

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT03605433. Non-randomized; no masking; primary purpose treatment. Start 2018-12-01 (anticipated); primary completion 2019-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT03605433, source copy `cardio:ctgov-nct03605433-2018-07-30`, retrieved 2026-10-26)
- Planned start: 2018-12-01 (anticipated) (ClinicalTrials.gov record NCT03605433, source copy `cardio:ctgov-nct03605433-2018-07-30`, retrieved 2026-10-26)
- Primary completion: 2019-12-31 (anticipated) (ClinicalTrials.gov record NCT03605433, source copy `cardio:ctgov-nct03605433-2018-07-30`, retrieved 2026-10-26)
- Completion: 2020-12-31 (anticipated) (ClinicalTrials.gov record NCT03605433, source copy `cardio:ctgov-nct03605433-2018-07-30`, retrieved 2026-10-26)
- Countries: Portugal (ClinicalTrials.gov record NCT03605433, source copy `cardio:ctgov-nct03605433-2018-07-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03605433-2018-07-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Surgical Revascularization Outcomes After Oral Anticoagulation or Antiplatelets
- Acronym: SCOOP
- Condition: Coronary Artery Disease
- Condition: Saphenous Vein Graft Patency
- Intervention (Drug): Rivaroxaban
- Lead sponsor: Unidade Local de Saúde de Coimbra, EPE
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)

## Provenance

Content hash: 1e610da1b1bd350c91d95399d8f2a67ec1d85e9872a8a29a90476ee0b20058a2
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
